ELUXA 1: Phase II global study of BI 1482694 (HM61713) in patients with T790M-positive non-small cell lung cancer after treatment #476TiP with an epidermal growth factor receptor tyrosine kinase inhibitor | boehringer-ingelheim.gr

DOWNLOAD PDF (3.86 MB)

ELUXA 1: Phase II global study of BI 1482694 (HM61713) in patients with T790M-positive non-small cell lung cancer after treatment #476TiP with an epidermal growth factor receptor tyrosine kinase inhibitor

View PDF of ELUXA 1: Phase II global study of BI 1482694 (HM61713) in patients with T790M-positive non-small cell lung cancer after treatment #476TiP with an epidermal growth factor receptor tyrosine kinase inhibitor